Clinical bottom line
Emerging therapies that modulate regulatory T cells (Tregs) represent a promising but still investigational approach for treating various autoimmune diseases. Early-phase clinical trials and preclinical studies suggest potential benefits in restoring immune tolerance and reducing disease activity by enhancing Treg number or function. However, robust evidence from large, controlled trials remains limited, and safety concerns, including risks of infection and malignancy, require careful monitoring. Clinicians should consider Treg-targeted therapies as experimental options within clinical trials or specialized settings until further data clarify their efficacy and safety profiles.
What the evidence shows
Regulatory T cells are critical for maintaining immune homeostasis and preventing autoimmunity by suppressing autoreactive effector T cells. Dysfunction or deficiency of Tregs has been implicated in multiple autoimmune diseases such as systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS), and rheumatoid arthritis (RA) [1,2]. Therapeutic strategies aiming to enhance Treg number or function include low-dose interleukin-2 (IL-2) therapy, adoptive Treg cell transfer, and agents targeting Treg-associated pathways (e.g., CTLA-4 agonists, epigenetic modulators).
Low-dose IL-2 therapy has garnered the most clinical attention. A systematic review and meta-analysis of phase 1 and 2 trials (2018–2023) in autoimmune diseases including SLE, T1D, and graft-versus-host disease (GVHD) demonstrated that low-dose IL-2 selectively expands Tregs and is associated with clinical improvement and acceptable safety in small cohorts [3]. For example, a randomized controlled trial in SLE patients showed that low-dose IL-2 increased circulating Tregs and reduced disease activity scores compared to placebo, with mild adverse events [4]. Similarly, early-phase trials in T1D suggest preservation of beta-cell function with IL-2–induced Treg expansion [5].
Adoptive Treg cell therapy, involving ex vivo expansion and reinfusion of autologous Tregs, is under active investigation. Initial phase 1/2 trials in autoimmune diseases and transplantation have demonstrated feasibility and safety, with some signals of efficacy [6]. However, challenges include Treg stability, manufacturing complexity, and long-term persistence.
Other novel agents targeting Treg pathways, such as low-dose rapamycin, CTLA-4–Ig fusion proteins, and epigenetic drugs, have shown immunomodulatory effects in preclinical models and early clinical studies but lack robust efficacy data in autoimmune populations [7].
Caveats and uncertainty
The current evidence base is limited by small sample sizes, short follow-up durations, and heterogeneity in autoimmune conditions studied. Most trials are early phase, focusing on safety and biological endpoints rather than definitive clinical outcomes. The durability of Treg expansion and functional improvement remains unclear. Additionally, the risk of immunosuppression-related infections or malignancies with chronic Treg modulation is not fully characterized.
Patient selection criteria and optimal dosing regimens for Treg-targeted therapies are not standardized. Autoimmune diseases are heterogeneous, and Treg dysfunction may vary by disease subtype and stage, complicating generalizability. Biomarkers to predict response or monitor therapy are under development but not yet validated.
Finally, adoptive Treg therapies face logistical and cost barriers that currently limit widespread clinical application.
How this may change practice
While not yet ready for routine clinical use, Treg modulation therapies may become important adjuncts or alternatives to conventional immunosuppression in autoimmune diseases. Clinicians should remain aware of ongoing clinical trials and emerging data, particularly for refractory or severe cases where conventional therapies fail.
In specialized centers, low-dose IL-2 therapy may be considered under research protocols or compassionate use, with careful patient monitoring. Adoption of adoptive Treg cell therapy awaits further evidence and regulatory approval.
Future integration of Treg-targeted therapies will likely depend on improved biomarkers for patient stratification, optimized dosing strategies, and long-term safety data. These approaches hold promise for more precise immune modulation with potentially fewer off-target effects compared to broad immunosuppressants.